About Us
Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders.
Venodol Roll-on
Venodol Roll-on Topical Analgesic
Spotlight Innovation subsidiary Caretta Therapeutics’ over-the-counter chronic pain relief product, Venodol Roll-on, is now available online at Venodol.com and Amazon.com. Venodol Roll-on topical analgesic is formulated to provide long-lasting relief from chronic pain associated with inflammation, including joint pain, tendinitis, arthritis (excluding osteoarthritis), and stubborn body aches.
Press Releases
- JULY 10, 2018 Spotlight Innovation Announces Partnership Agreement with At-Risk Youth Organization Hip-Hope
- MARCH 13, 2018 Newly Issued U.S. Patent Covers Spotlight Innovation’s Spinal Muscular Atrophy Drug Candidates
- JANUARY 11, 2018 Venodol Roll-on, Spotlight Innovation’s New Analgesic Product, Now Available at Amazon.com
- SEPTEMBER 27, 2017 Spotlight Innovation Forms Corporate Partnership with University of Iowa Athletics to Promote New Chronic Pain Relief Product “Venodol”
- AUGUST 16, 2017 Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for Spinal Muscular Atrophy
- JUNE 30, 2017 Spotlight Innovation Enters into Sponsored Research Agreement to Develop New Therapies for Spinal Muscular Atrophy